Literature DB >> 10507286

Determination of equid herpesvirus 1-specific, CD8+, cytotoxic T lymphocyte precursor frequencies in ponies.

T O'Neill1, J H Kydd, G P Allen, E Wattrang, J A Mumford, D Hannant.   

Abstract

The frequency of antigen-specific, genetically restricted cytotoxic T lymphocyte precursors (CTLp) was measured in peripheral blood mononuclear cells (PBMC) of ponies before and after infection with equid herpesvirus 1 (EHV1). Split-well limiting dilution analysis (LDA) was developed to measure CTLp frequency using EHV1-infected 51Cr-labelled lymphoblasts as targets. Extensive characterisation showed that recombinant human interleukin-2, autologous antigen presenting cells and equine serum containing virus neutralising antibody were necessary for maturation of CTLp into effector CTL in vitro. CTLs were not induced when the equine serum (containing VN antibody) was replaced with either foetal calf serum or foetal equine serum (without VN antibody), or seronegative equine serum. CTLp frequency decreased significantly when CD8+ lymphocytes were depleted from the induction cultures. There was good inter- and intra-assay reproducibility using both fresh and recovered cryopreserved PBMC. Both EHV1 and EHV4 could be used to induce effector CTL which lysed EHV1-infected target cells. CTLp frequencies were measured in 2 groups of ponies: Group 1 consisted of two ponies (approx. 9 years old), which had multiple previous experimental infections with EHV1; Group 2 comprised five young (1-2 years) and two older (7 years) ponies which had presumed natural exposure to EHV1/EHV4 but no previous experimental infections. The results showed that CTLp frequencies were higher in the ponies of Group 1 compared with the others. Moreover, ponies with the higher CTLp frequencies were better protected against re-challenge infection with EHV1, showing reduced or absent clinical and virological signs. Consequently, measurement of EHV1-specific CTLp frequency is a potential in vitro correlate of immunity which may be useful for screening new vaccines in horses before embarking upon challenge protection studies to confirm efficacy.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10507286     DOI: 10.1016/s0165-2427(99)00037-9

Source DB:  PubMed          Journal:  Vet Immunol Immunopathol        ISSN: 0165-2427            Impact factor:   2.046


  9 in total

1.  Equine Herpesvirus Type 1 Enhances Viral Replication in CD172a+ Monocytic Cells upon Adhesion to Endothelial Cells.

Authors:  Kathlyn Laval; Herman W Favoreel; Katrien C K Poelaert; Jolien Van Cleemput; Hans J Nauwynck
Journal:  J Virol       Date:  2015-08-19       Impact factor: 5.103

2.  The common equine class I molecule Eqca-1*00101 (ELA-A3.1) is characterized by narrow peptide binding and T cell epitope repertoires.

Authors:  Tobias Bergmann; Carrie Moore; John Sidney; Donald Miller; Rebecca Tallmadge; Rebecca M Harman; Carla Oseroff; Amanda Wriston; Jeffrey Shabanowitz; Donald F Hunt; Nikolaus Osterrieder; Bjoern Peters; Douglas F Antczak; Alessandro Sette
Journal:  Immunogenetics       Date:  2015-09-23       Impact factor: 2.846

3.  Immunological correlates of vaccination and infection for equine herpesvirus 1.

Authors:  Laura B Goodman; Christine Wimer; Edward J Dubovi; Carvel Gold; Bettina Wagner
Journal:  Clin Vaccine Immunol       Date:  2011-12-28

4.  Early detection of dominant Env-specific and subdominant Gag-specific CD8+ lymphocytes in equine infectious anemia virus-infected horses using major histocompatibility complex class I/peptide tetrameric complexes.

Authors:  Robert H Mealey; Amin Sharif; Shirley A Ellis; Matt H Littke; Steven R Leib; Travis C McGuire
Journal:  Virology       Date:  2005-08-15       Impact factor: 3.616

5.  Generation of a candidate live marker vaccine for equine arteritis virus by deletion of the major virus neutralization domain.

Authors:  Javier Castillo-Olivares; Roeland Wieringa; Tamás Bakonyi; Antoine A F de Vries; Nick J Davis-Poynter; Peter J M Rottier
Journal:  J Virol       Date:  2003-08       Impact factor: 5.103

6.  Deletion of the ORF2 gene of the neuropathogenic equine herpesvirus type 1 strain Ab4 reduces virulence while maintaining strong immunogenicity.

Authors:  Christiane L Schnabel; Christine L Wimer; Gillian Perkins; Susanna Babasyan; Heather Freer; Christina Watts; Alicia Rollins; Nikolaus Osterrieder; Bettina Wagner
Journal:  BMC Vet Res       Date:  2018-08-22       Impact factor: 2.741

Review 7.  EHV-1: A Constant Threat to the Horse Industry.

Authors:  Fatai S Oladunni; David W Horohov; Thomas M Chambers
Journal:  Front Microbiol       Date:  2019-12-03       Impact factor: 5.640

8.  Transcriptomic Profiling of Equine and Viral Genes in Peripheral Blood Mononuclear Cells in Horses during Equine Herpesvirus 1 Infection.

Authors:  Lila M Zarski; Patty Sue D Weber; Yao Lee; Gisela Soboll Hussey
Journal:  Pathogens       Date:  2021-01-07

9.  A Live-Attenuated Equine Influenza Vaccine Stimulates Innate Immunity in Equine Respiratory Epithelial Cell Cultures That Could Provide Protection From Equine Herpesvirus 1.

Authors:  Lila M Zarski; Wendy E Vaala; D Craig Barnett; Fairfield T Bain; Gisela Soboll Hussey
Journal:  Front Vet Sci       Date:  2021-06-10
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.